Editas Medicine Management
Management criteria checks 2/4
Editas Medicine's CEO is Gilmore O’Neill, appointed in Jun 2022, has a tenure of 2.67 years. total yearly compensation is $2.39M, comprised of 26.8% salary and 73.2% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth $150.64K. The average tenure of the management team and the board of directors is 1.8 years and 6 years respectively.
Key information
Gilmore O’Neill
Chief executive officer
US$2.4m
Total compensation
| CEO salary percentage | 26.8% |
| CEO tenure | 2.7yrs |
| CEO ownership | 0.1% |
| Management average tenure | 1.8yrs |
| Board average tenure | 6yrs |
Recent management updates
Recent updates
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
Jan 17Little Excitement Around Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues As Shares Take 34% Pounding
Nov 20
Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week
Nov 06Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Sep 26Editas Medicine: A Risk/Reward Worth Considering
Sep 25Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet
Aug 23Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 10Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results
May 12The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%
Apr 23Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Mar 09Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch
Feb 28New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)
Dec 15Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
May 10Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Jan 19Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline
Oct 18Editas Medicine started at neutral at BofA due to competition in gene editing programs
Sep 29We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely
Sep 13Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies
Aug 23Editas Medicine Q2 2022 Earnings Preview
Aug 02Baisong Mei joins Editas Medicine as Chief Medical Officer
Jul 18Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?
Jun 12Editas: Tackling Rare Eye Disease With Use Of Crispr Technology
Jun 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$211m |
| Jun 30 2024 | n/a | n/a | -US$193m |
| Mar 31 2024 | n/a | n/a | -US$166m |
| Dec 31 2023 | US$2m | US$641k | -US$153m |
| Sep 30 2023 | n/a | n/a | -US$195m |
| Jun 30 2023 | n/a | n/a | -US$206m |
| Mar 31 2023 | n/a | n/a | -US$219m |
| Dec 31 2022 | US$9m | US$356k | -US$220m |
Compensation vs Market: Gilmore's total compensation ($USD2.39M) is above average for companies of similar size in the US market ($USD638.32K).
Compensation vs Earnings: Gilmore's compensation has been consistent with company performance over the past year.
CEO
Gilmore O’Neill (60 yo)
2.7yrs
Tenure
US$2,392,309
Compensation
Dr. Gilmore O’Neill, M.B., M. M.SC., serves as Member of Scientific Advisory Board of AavantiBio, Inc. since February 2022. He is President & CEO of Editas Medicine, Inc. from June 01, 2022 and serves as i...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.7yrs | US$2.39m | 0.13% $ 150.6k | |
| CFO & Executive VP | 1.8yrs | US$2.69m | 0.028% $ 31.7k | |
| Executive VP & Chief Scientific Officer | 1.6yrs | US$1.73m | 0.018% $ 19.8k | |
| Co-Founder & Scientific Advisory Board Member | 12.1yrs | no data | no data | |
| Co-Founder & Scientific Advisory Board Member | 12.1yrs | no data | no data | |
| Executive VP and Chief Technical & Quality Officer | less than a year | no data | no data | |
| Senior VP of Corporate Communications & Investor Relations | no data | no data | no data | |
| Executive VP & General Counsel | no data | no data | no data | |
| Executive VP & Chief People Officer | 1.9yrs | no data | no data | |
| Executive VP and Chief Commercial & Strategy Officer | 1.4yrs | no data | no data |
1.8yrs
Average Tenure
59.5yo
Average Age
Experienced Management: EDIT's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | no data | US$2.39m | 0.13% $ 150.6k | |
| Co-Founder & Scientific Advisory Board Member | no data | no data | no data | |
| Co-Founder & Scientific Advisory Board Member | no data | no data | no data | |
| Independent Director | 7.8yrs | US$210.56k | 0.0024% $ 2.7k | |
| Independent Chairman | 7yrs | US$231.07k | 0.082% $ 92.7k | |
| Independent Director | 1.8yrs | US$264.88k | 0% $ 0 | |
| Independent Director | 6yrs | US$213.06k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$215.06k | 0% $ 0 |
6.0yrs
Average Tenure
66yo
Average Age
Experienced Board: EDIT's board of directors are considered experienced (6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 22:58 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Editas Medicine, Inc. is covered by 31 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Joel Beatty | Baird |
| Huidong Wang | Barclays |